Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 2627)

VOLUNTARY ANNOUNCEMENT FINANCIAL PERFORMANCE AND BUSINESS OPERATIONS FOR THE THIRD QUARTER OF 2026 AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the "**Company**", together with its subsidiary, the "**Group**") on a voluntary basis to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the latest financial performance and business operations of the Group.

FINANCIAL PERFORMANCE AND BUSINESS OPERATIONS FOR THE THIRD QUARTER OF 2026

The board (the "**Board**") of directors (the "**Director(s)**") of the Company hereby announces that, based on information currently available to the Company and the Board's preliminary review of the unaudited management accounts of the Group for the three months ended September 30, 2026 (the "**Third Quarter of 2026**"), the Group recorded a revenue of approximately RMB322 million in the Third Quarter of 2026, representing an increase of approximately 3.5% as compared to the corresponding period of last year; and a net profit of approximately RMB59 million, representing an increase of approximately 15.5% as compared to the corresponding period of last year. The Board is of the view that the Group achieved year-on-year growth in both revenue and net profit in the Third Quarter of 2026, among which the increase in net profit was more distinct, primarily attributable to: (i) the production batches and production volume of the Group's trivalent subunit influenza vaccine in the Third Quarter of 2026 increased as compared to the corresponding period of last year, resulting in an improvement in the capacity utilization rate; (ii) the Group continued to optimize its internal management and streamline its operational procedures in the Third Quarter of 2026, resulting in a decrease in administrative expenses as compared to the corresponding period of last year; and (iii) the research and development expenses in the Third Quarter of 2026 decreased accordingly as compared to the corresponding period of last year, along with the optimization of the pace of research and development investments. The revenue growth of the Group for the Third Quarter of 2026 was relatively moderate, which was primarily attributable to: (i) since 2026, the applicable value-added tax collection rate for the Group's products has been adjusted upward from 3% to 13%, which led to a relatively slower growth in the unit sales revenue of products for the Third Quarter of 2026; and (ii) the unit selling price of the trivalent subunit influenza vaccine is approximately 7% lower than that of the quadrivalent subunit influenza vaccine. As the proportion of sales of the trivalent subunit influenza vaccine increased in the Third Quarter of 2026, the overall average unit selling price decreased accordingly, resulting in the revenue growth rate being lower than the sales volume growth rate.

In the Third Quarter of 2026, the production, supply, and lot release of the Company's subunit influenza vaccines continued to progress in an orderly manner, maintaining a stable product supply. In terms of production, after obtaining the commercialization approval of the trivalent subunit influenza vaccine in early 2026, the Group successively completed the production of such finished vaccines. All batches passed internal quality inspections and have been submitted for biologics lot release applications. As of September 30, 2026, the Group's influenza bulk workshop and influenza formulation workshop completed 100% and 93.9% of their annual production targets, respectively. In terms of lot release, the Group completed a total of 30 batches of biologics lot release applications as of the end of the Third Quarter of 2026, of which 17 batches obtained biologics lot release certificates prior to September 30, 2026. As of the date of this announcement, the remaining 13 batches have also obtained the relevant certificates. In terms of quality management, the Group passed the Good Manufacturing Practice for Drugs (GMP) compliance inspection of Jiangsu Province in the Third Quarter of 2026. As of the date of this announcement, the Group has passed one national vaccine inspection and two GMP compliance inspections of Jiangsu Province in 2026. In the fourth quarter of 2026, the Group will continue to cater to the market demand of the domestic influenza vaccination season, continuously advance the production, lot release, and market distribution of the trivalent subunit influenza vaccine, and the Group's sufficient inventory and supply chain reserves will also safeguard the sustained growth in sales.

The Board is also pleased to announce that the Company's project "Commercialization of a Class I New Drug Quadrivalent Subunit Influenza Vaccine and its Promotion and Application among Special Populations" (一類新藥四價流感病毒亞單位疫苗商業化及特殊人群的推廣應用) has recently been awarded the Third Prize of the Jiangsu Provincial Science and Technology Progress Award presented by the Jiangsu Provincial People's Government. Such award represents an official recognition of the technological maturity, industrialization capability and application value in special populations of the Company's core product, which also provides robust support for the Company's subsequent further expansion of market coverage and quality assurance of product supply.

The Board wishes to emphasize that the financial information contained in this announcement is only a preliminary assessment by the management of the Company based on the unaudited consolidated management accounts of the Group for the Third Quarter of 2026. Such financial information contained in this announcement has not been audited or reviewed by the Company's auditor and is subject to adjustments and changes, including those from the outcome and findings of the independent forensic investigation and the independent internal control review, as well as the completion of the relevant financial reporting, audit and review procedures.

ABOUT Ab&B Bio-Tech

Ab&B Bio-Tech is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. In formulating our pipeline, we closely track global trends in infectious disease incidence and vaccine R&D, with a strategic focus on premium vaccines, aiming to replace traditional vaccines and imported vaccines in China and establish our presence in international markets. Our range of products include but are not limited to, the quadrivalent subunit influenza vaccine, the trivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with other vaccine candidates.

CONTINUED SUSPENSION OF TRADING

Trading in the H Shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of our Board and general manager

Hong Kong, November 17, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai and Mr. HE Yiming as executive Directors; (ii) Mr. DU Mu as non-executive Director; and (iii) Mr. LI Xiangming, Mr. LI Jianjun, Mr. CHEN Chengbei and Ms. LUI Mei Ka as independent non-executive Directors.